US venture capital firm
Before joining SVLS, Cameron was appointed CEO of Cambridge Antibody Technology, following its acquisition by Astra Zeneca in 2006. Prior to that, he held a series of senior positions at Astra Zeneca including head of the cardiovascular therapy area, global head of medical tesearch and member of the R&D leadership team. Cameron started his industry career with Janssen, after working as a physician in the UK.